The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
Investor's Business Daily on MSN1h
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer DrugAstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...
AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback